2bnq: Difference between revisions
No edit summary |
No edit summary |
||
Line 2: | Line 2: | ||
<StructureSection load='2bnq' size='340' side='right' caption='[[2bnq]], [[Resolution|resolution]] 1.70Å' scene=''> | <StructureSection load='2bnq' size='340' side='right' caption='[[2bnq]], [[Resolution|resolution]] 1.70Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[2bnq]] is a 5 chain structure with sequence from [http://en.wikipedia.org/wiki/ | <table><tr><td colspan='2'>[[2bnq]] is a 5 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2BNQ OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2BNQ FirstGlance]. <br> | ||
</td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[1a1m|1a1m]], [[1a1n|1a1n]], [[1a1o|1a1o]], [[1a6z|1a6z]], [[1a9b|1a9b]], [[1a9e|1a9e]], [[1agb|1agb]], [[1agc|1agc]], [[1agd|1agd]], [[1age|1age]], [[1agf|1agf]], [[1akj|1akj]], [[1ao7|1ao7]], [[1b0g|1b0g]], [[1b0r|1b0r]], [[1bd2|1bd2]], [[1ce6|1ce6]], [[1de4|1de4]], [[1duy|1duy]], [[1duz|1duz]], [[1e27|1e27]], [[1e28|1e28]], [[1efx|1efx]], [[1exu|1exu]], [[1gzp|1gzp]], [[1gzq|1gzq]], [[1hhg|1hhg]], [[1hhh|1hhh]], [[1hhi|1hhi]], [[1hhj|1hhj]], [[1hhk|1hhk]], [[1hla|1hla]], [[1hsa|1hsa]], [[1hsb|1hsb]], [[1i1f|1i1f]], [[1i1y|1i1y]], [[1i4f|1i4f]], [[1i7r|1i7r]], [[1i7t|1i7t]], [[1i7u|1i7u]], [[1im3|1im3]], [[1im9|1im9]], [[1jf1|1jf1]], [[1jge|1jge]], [[1jnj|1jnj]], [[1jht|1jht]], [[1qlf|1qlf]], [[1qqd|1qqd]], [[1qr1|1qr1]], [[1qrn|1qrn]], [[1qse|1qse]], [[1qsf|1qsf]], [[1k5n|1k5n]], [[1kpr|1kpr]], [[1ktl|1ktl]], [[1lds|1lds]], [[1of2|1of2]], [[1fyt|1fyt]], [[1kgc|1kgc]], [[1tmc|1tmc]], [[2clr|2clr]], [[2hla|2hla]], [[2bnr|2bnr]], [[3hla|3hla]]</td></tr> | </td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[1a1m|1a1m]], [[1a1n|1a1n]], [[1a1o|1a1o]], [[1a6z|1a6z]], [[1a9b|1a9b]], [[1a9e|1a9e]], [[1agb|1agb]], [[1agc|1agc]], [[1agd|1agd]], [[1age|1age]], [[1agf|1agf]], [[1akj|1akj]], [[1ao7|1ao7]], [[1b0g|1b0g]], [[1b0r|1b0r]], [[1bd2|1bd2]], [[1ce6|1ce6]], [[1de4|1de4]], [[1duy|1duy]], [[1duz|1duz]], [[1e27|1e27]], [[1e28|1e28]], [[1efx|1efx]], [[1exu|1exu]], [[1gzp|1gzp]], [[1gzq|1gzq]], [[1hhg|1hhg]], [[1hhh|1hhh]], [[1hhi|1hhi]], [[1hhj|1hhj]], [[1hhk|1hhk]], [[1hla|1hla]], [[1hsa|1hsa]], [[1hsb|1hsb]], [[1i1f|1i1f]], [[1i1y|1i1y]], [[1i4f|1i4f]], [[1i7r|1i7r]], [[1i7t|1i7t]], [[1i7u|1i7u]], [[1im3|1im3]], [[1im9|1im9]], [[1jf1|1jf1]], [[1jge|1jge]], [[1jnj|1jnj]], [[1jht|1jht]], [[1qlf|1qlf]], [[1qqd|1qqd]], [[1qr1|1qr1]], [[1qrn|1qrn]], [[1qse|1qse]], [[1qsf|1qsf]], [[1k5n|1k5n]], [[1kpr|1kpr]], [[1ktl|1ktl]], [[1lds|1lds]], [[1of2|1of2]], [[1fyt|1fyt]], [[1kgc|1kgc]], [[1tmc|1tmc]], [[2clr|2clr]], [[2hla|2hla]], [[2bnr|2bnr]], [[3hla|3hla]]</td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2bnq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2bnq OCA], [http://www.rcsb.org/pdb/explore.do?structureId=2bnq RCSB], [http://www.ebi.ac.uk/pdbsum/2bnq PDBsum]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2bnq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2bnq OCA], [http://pdbe.org/2bnq PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=2bnq RCSB], [http://www.ebi.ac.uk/pdbsum/2bnq PDBsum]</span></td></tr> | ||
</table> | </table> | ||
== Function == | == Function == | ||
Line 26: | Line 26: | ||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
</div> | </div> | ||
<div class="pdbe-citations 2bnq" style="background-color:#fffaf0;"></div> | |||
==See Also== | ==See Also== | ||
Line 35: | Line 36: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: | [[Category: Human]] | ||
[[Category: Bossi, G]] | [[Category: Bossi, G]] | ||
[[Category: Boultier, J M]] | [[Category: Boultier, J M]] |
Revision as of 20:44, 10 September 2015
STRUCTURAL AND KINETIC BASIS FOR HEIGHTENED IMMUNOGENICITY OF T CELL VACCINESSTRUCTURAL AND KINETIC BASIS FOR HEIGHTENED IMMUNOGENICITY OF T CELL VACCINES
Structural highlights
Function[1A02_HUMAN] Involved in the presentation of foreign antigens to the immune system. Evolutionary Conservation![]() Check, as determined by ConSurfDB. You may read the explanation of the method and the full data available from ConSurf. Publication Abstract from PubMedAnalogue peptides with enhanced binding affinity to major histocompatibility class (MHC) I molecules are currently being used in cancer patients to elicit stronger T cell responses. However, it remains unclear as to how alterations of anchor residues may affect T cell receptor (TCR) recognition. We correlate functional, thermodynamic, and structural parameters of TCR-peptide-MHC binding and demonstrate the effect of anchor residue modifications of the human histocompatibility leukocyte antigens (HLA)-A2 tumor epitope NY-ESO-1(157-165)-SLLMWITQC on TCR recognition. The crystal structure of the wild-type peptide complexed with a specific TCR shows that TCR binding centers on two prominent, sequential, peptide sidechains, methionine-tryptophan. Cysteine-to-valine substitution at peptide position 9, while optimizing peptide binding to the MHC, repositions the peptide main chain and generates subtly enhanced interactions between the analogue peptide and the TCR. Binding analyses confirm tighter binding of the analogue peptide to HLA-A2 and improved soluble TCR binding. Recognition of analogue peptide stimulates faster polarization of lytic granules to the immunological synapse, reduces dependence on CD8 binding, and induces greater numbers of cross-reactive cytotoxic T lymphocyte to SLLMWITQC. These results provide important insights into heightened immunogenicity of analogue peptides and highlight the importance of incorporating structural data into the process of rational optimization of superagonist peptides for clinical trials. Structural and kinetic basis for heightened immunogenicity of T cell vaccines.,Chen JL, Stewart-Jones G, Bossi G, Lissin NM, Wooldridge L, Choi EM, Held G, Dunbar PR, Esnouf RM, Sami M, Boulter JM, Rizkallah P, Renner C, Sewell A, van der Merwe PA, Jakobsen BK, Griffiths G, Jones EY, Cerundolo V J Exp Med. 2005 Apr 18;201(8):1243-55. PMID:15837811[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
|
Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)
OCA- Human
- Bossi, G
- Boultier, J M
- Cerundolo, V
- Chen, J L
- Choi, E M.L
- Dunbar, P R
- Esnouf, R M
- Griffiths, G
- Held, G
- Jackobsen, B K
- Jones, E Y
- Lissin, N M
- Merwe, P A.Van Der
- Renner, C
- Rizkallah, P
- Sami, M
- Sewell, A
- Stewart-Jones, G
- Wooldridge, L
- Complex
- Flu
- Glycoprotein
- Immune system-receptor complex
- Immune system-receptor-complex
- Immune system/receptor
- Immunodominance
- Mhc
- Receptor
- Superagonist peptide t-cell vaccine
- T-cell
- Tcr
- Transmembrane